• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Te

  2026-06-19

  DiI (DiIC18(3)) enables robust, selective plasma membrane labeling for live and fixed cell systems, supporting neuronal tracing, cell migration, and membrane analysis workflows. It is not suitable for water-based protocols or intracellular organelle targeting. Researchers should strictly adhere to solvent compatibility and workflow best practices to ensure reproducibility and signal specificity.

• Pharmacokinetic Variability of CSBTA in MASH: Mechanistic In

  2026-06-19

  This study advances understanding of how disease state and transporter/enzyme modulation affect the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in high-fat, high-cholesterol diet-induced MASH mice. The findings highlight the importance of considering both pathological status and transporter activity when optimizing dosing regimens for metabolic liver disease therapies.

• Psora 4: Advanced Kv1.3 Blocker for Targeted T Cell Modulati

  2026-06-18

  Psora 4 stands out as a selective Kv1.3 blocker for dissecting effector memory T cell function and Ca2+ signaling, offering high specificity and reproducibility for both in vitro and in vivo immune models. This guide translates recent mechanistic insights and protocol benchmarks into actionable workflows, ensuring robust results and troubleshooting clarity for advanced immunology research.

• Hexetidine (NSC-17764): Protocol Optimization for Oral Biofi

  2026-06-18

  Hexetidine (NSC-17764) delivers robust, reproducible inhibition of oral pathogens and biofilm formation where other antimicrobials may falter. This article translates breakthrough findings on adsorption effects and practical workflows into actionable guidance for oral infection and dental plaque research.

• SAR131675: VEGFR-3 Inhibitor for Anti-Lymphangiogenic Resear

  2026-06-17

  SAR131675 stands out as a highly selective VEGFR-3 inhibitor, empowering researchers to dissect lymphangiogenesis and macrophage-driven disease pathways with unprecedented specificity. Its validated potency, robust selectivity, and clear performance metrics equip labs to model tumor growth inhibition, fibrosis, and vascular remodeling with confidence.

• Hepatic sEH–Nrf2 Axis Drives Osteoclastogenesis in Osteoporo

  2026-06-17

  A recent study uncovers how hepatic soluble epoxide hydrolase (sEH) promotes osteoclast formation in osteoporosis via suppression of the Nrf2 antioxidant pathway, defining a novel liver-bone axis. These findings highlight new opportunities for targeting redox signaling in bone disease research.

• Gap19: Selective Connexin 43 Hemichannel Blocker for Neuropr

  2026-06-16

  Gap19 is a selective connexin 43 hemichannel blocker that modulates neuroglial and immune signaling with high specificity. Its unique mechanism enables inhibition of ATP release in astrocytes and confers neuroprotection in cerebral ischemia without affecting gap junction channels. Extensive evidence supports its research use in ischemic brain injury and macrophage polarization.

• CB-5083 in Stress Granule and ER Stress Homeostasis: New Hor

  2026-06-16

  Explore how the potent p97 inhibitor CB-5083 unlocks novel research into stress granule regulation, ER stress, and protein homeostasis disruption. This article delivers a deeper mechanistic perspective and practical workflow insights for oncology and neurodegeneration fields.

• EPI-001: Redefining AR N-Terminal Inhibition in Oncology

  2026-06-15

  This thought-leadership article explores the mechanistic and translational relevance of EPI-001, an androgen receptor N-terminal domain inhibitor, for overcoming resistance in prostate and triple-negative breast cancer. Integrating mechanistic insight, experimental evidence, and strategic guidance, it bridges gaps between standard product content and the strategic needs of translational researchers.

• Epalrestat: Aldose Reductase Inhibitor for Neuroprotection M

  2026-06-15

  Epalrestat is redefining neurodegenerative disease research by combining polyol pathway inhibition with direct KEAP1/Nrf2 pathway activation. This guide details how to deploy Epalrestat in oxidative stress and Parkinson’s models, with actionable workflow enhancements and troubleshooting tips for reproducible results.

• Q-VD(OMe)-OPh: Precision Caspase Inhibition in Apoptosis Ass

  2026-06-14

  Q-VD(OMe)-OPh empowers apoptosis research with superior, low-toxicity pan-caspase inhibition, enabling robust cell death assay design even in challenging models of cancer resistance and neuroprotection. This article distills best practices, protocol parameters, and troubleshooting strategies to maximize reproducibility and data fidelity across advanced experimental workflows.

• Bismuth Subsalicylate in GI Disorder Research: Protocols & P

  2026-06-13

  Bismuth Subsalicylate empowers researchers with high-purity, robust inhibition of prostaglandin pathways for advanced gastrointestinal and inflammation studies. This guide translates bench research and reference workflows into actionable protocols, troubleshooting insights, and comparative strategies for optimizing GI disorder experiments.

• ATF4’s Role in Mitigating Doxorubicin-Induced Cardiotoxicity

  2026-06-12

  This study uncovers a novel antioxidative mechanism by which ATF4 protects against doxorubicin-induced cardiomyopathy. The findings highlight the KLF16-ATF4-CSE-H2S axis as a potential therapeutic target for reducing cardiac damage during cancer chemotherapy.

• KX2-391 Dihydrochloride: Applied Protocols for Dual Pathway

  2026-06-12

  KX2-391 dihydrochloride stands out as a dual Src kinase and tubulin polymerization inhibitor, empowering researchers with specificity in oncology and antiviral workflows. This article unpacks practical protocol enhancements, troubleshooting strategies, and novel findings that maximize the translational value of Tirbanibulin dihydrochloride in both cancer and HBV models.

• VX-661 F508del CFTR Corrector: Precision Workflows in CF Res

  2026-06-11

  VX-661 (F508del CFTR corrector) empowers cystic fibrosis researchers with robust, quantifiable rescue of misfolded CFTR, especially when protocol design leverages the latest insights into proteostasis and calnexin-dependence. This guide delivers actionable workflows, troubleshooting strategies, and evidence-based protocol parameters to maximize the translational value of VX-661 in varied experimental contexts.

451 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page